Investigating a vaccine for preventing cancer in patients with Lynch Syndrome
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome
This study is testing a new vaccine designed to help prevent cancer in people with Lynch Syndrome, a genetic condition that raises the risk of colorectal cancer, using a special model to see how safe and effective it is.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10894856 on NIH RePORTER |
What this research studies
This research focuses on developing a vaccine aimed at preventing cancer in individuals with Lynch Syndrome, a hereditary condition that significantly increases the risk of colorectal cancer. The study utilizes a non-human primate model to evaluate the safety and effectiveness of the vaccine, which targets specific neoantigens generated by mutations in the DNA mismatch repair genes. By analyzing immune responses and the potential for cancer prevention, the research aims to translate findings into human applications. Patients with Lynch Syndrome may benefit from insights gained through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Lynch Syndrome who are at high risk for developing colorectal cancer.
Not a fit: Patients without Lynch Syndrome or those who do not have a genetic predisposition to colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a preventive vaccine that significantly reduces cancer risk for patients with Lynch Syndrome.
How similar studies have performed: Previous research has shown promise in using vaccines targeting neoantigens for cancer prevention, indicating a potential for success in this novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.